Definitive Contract 75N93021C00043
Award Date
9/3/21
Potential Completion Date
8/31/22
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27701, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $220,582 Small Business Innovation Research (SBIR) Phase I contract to Oak Therapeutics Inc., a pharmaceutical company based in Westlake Village, California. The contract is for the development of oral dissolving strips for the delivery of isoniazid, a medication used to treat tuberculosis, in children and adults. This contract is a Firm Fixed Price definitive...
This is a firm fixed-price purchase order awarded to Zymeron Corporation, a minority-owned small business, under the Department of the Army Medical Command's Small Business Innovation Research (SBIR) program. The $250,000.00 Phase I contract is for the research and development of a "Novel Aerosol Therapy for Immediate and Sustained ARDS Management". Zymeron, a biotechnology company focused on areas like drug delivery systems, will perform this medical research at its facilities in...
This is a $1,486,937 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of an inhaled drug combination for tuberculosis therapy under the SBIR Phase II program. Key tasks include the manufacture of spray-dried combination drugs, technical support for pharmacokinetic and...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,995 firm fixed-price contract to Via Therapeutics, LLC, a small business located in Austin, Texas. The contract is for the development of low-cost, shelf-stable, patient-adaptable clofazimine mini-tablets to treat tuberculosis in pediatric patients. This contract supports Via Therapeutics' pharmaceutical research and development efforts related to...
This SBIR Phase I contract from the National Institutes of Health and National Institute of Allergy and Infectious Diseases aims to develop a novel HIV vaccine co-delivery system. Zymeron Corporation will receive $300,000 to create an injectable thermosensitive hydrogel encapsulating polyroxatane-based self-amplifying RNA nanoparticles and GM-CSF cytokine adjuvant for targeted delivery. The research will take place in Research Triangle Park, North Carolina over approximately 22 months. This...
Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation...
This is a $167,489.14 firm fixed-price purchase order awarded by the U.S. Army Medical Command (MEDCOM) to Zymeron Corporation, a minority-owned small business, under the Army's SBIR (Small Business Innovation Research) Phase I program. The contract is for the development of "Rapid Point of Care Diagnostic Tests to Determine Dengue Serostatus", which aims to create a point-of-care test to assess past exposure to the dengue virus. The contract has a completion date of January 2, 2021....
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded Genscript USA Inc. a $1.4 million firm-fixed-price purchase order contract to synthesize, validate, and deliver approximately 132,000 peptides spanning the entire tuberculosis proteome. This contract, set aside for small businesses, was competitively awarded under a solicitation seeking peptide synthesis services to create a library of peptides that will support tuberculosis research efforts. Work...